Related Experiment Video
Updated: Sep 11, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
Tucuma Fat-Based Nanostructured Lipid Carriers: Physical Stability and Antifungal Activity
Antônio Taylon Aguiar Gomes1, Rayanne Rocha Pereira2, Lindalva Maria de Meneses Costa Ferreira1
1Institute of Health Sciences, Federal University of Pará, Belém, Pará 66075-110, Brazil.
Abstract:
This study aimed to obtain and characterize NLCs from tucuma fat and evaluate them against fungal cultures. The NLCs were obtained by high-pressure homogenization of tucuma fat and carnauba wax as the oil phase and were evaluated for encapsulation efficiency (EE), drug loading (DL), zeta potential, particle size, and in vitro release kinetics over a 70-day period. Four formulations (NLC1, NLC2, NLC3, and NLC4) were prepared, showing particle size variation between 109.7 and 241.1 nm, PDI ranging from 0.16 to 0.41, and zeta potential between -12.7 mW and -27.5 mW. Only two of the four formulations were loaded with ketoconazole, presenting encapsulation efficiencies between 43.55% (NLC3) and 80.97% (NLC4), while drug loading values ranged from 2.18% (NLC3) to 4.03% (NLC4). After 70 days of storage at 8 and 28 °C, they maintained their physical characteristics (particle size, zeta potential, and PDI). The release kinetics of NLC3 and NLC4 were explained by the Korsmeyer-Peppas mathematical model. Finally, the antifungal activity of ketoconazole was improved 8-fold in NLC3 and NLC4. Finally, tucuma NLCs showed physical stability and biological efficacy.
Related Concept Videos
Antifungal Agents
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Bioavailability Enhancement: Drug Permeability Enhancement
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Drugs that Stabilize Microtubules

